FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop

Z Bing, J Han, Z Zheng, N Liang - Life Sciences, 2021 - Elsevier
Gefitinib is tyrosine kinase inhibitor of epidermal growth factor receptor, which exhibits
notable clinical efficacy in non-small-cell lung cancer (NSCLC) treatment. However, gefitinib …
被引用次数：17 相关文章

FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop

Z Bing, J Han, Z Zheng, N Liang - Life sciences, 2021 - pubmed.ncbi.nlm.nih.gov
Gefitinib is tyrosine kinase inhibitor of epidermal growth factor receptor, which exhibits
notable clinical efficacy in non-small-cell lung cancer (NSCLC) treatment. However, gefitinib …

FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop.

Z Bing, J Han, Z Zheng, N Liang - Life Sciences, 2021 - europepmc.org
Gefitinib is tyrosine kinase inhibitor of epidermal growth factor receptor, which exhibits
notable clinical efficacy in non-small-cell lung cancer (NSCLC) treatment. However, gefitinib …

[引用][C] FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop

Z Bing, J Han, Z Zheng, N Liang - 2021